Group 1 - The core viewpoint of the news is that 越疆 (02432) has entered into a strategic cooperation agreement with 药师帮股份有限公司 (09885) to explore the integration of robotics and AI in the pharmaceutical industry [1][2] - The collaboration will focus on pharmaceutical collaborative robots, AI large models, and drug IoT technology, aiming to enhance applications in drug research, storage, distribution, retail, and medication services [1] - The first phase of the cooperation will target the deployment of collaborative robots in pharmacies and drug warehouses, with a feasibility study and technical assessments already completed [1] Group 2 - Both parties will adhere to principles of collaborative innovation and mutual development, sharing technical data and newly generated intellectual property and trade secrets [2] - The agreement grants the group exclusive production rights for the robots, while 药师帮 will have exclusive sales rights in the pharmaceutical sector [2] - The board of the group believes that this strategic partnership will facilitate resource integration, collaborative innovation, and promote technological advancement in the industry, ultimately benefiting social health [2]

Group 1 - The core viewpoint of the articles is that the strategic partnership between Yaoshi Bang and Yuezhi Technology aims to leverage their industry advantages and collaborative ecosystem to enhance the integration of robotics and the pharmaceutical industry, focusing on applications in drug development, storage, distribution, and retail services [1][2] - The initial phase of the collaboration will focus on the pharmacy and warehouse robotics sector, with the first project already planned and feasibility studies completed [1][2] - Both companies will share technical resources and newly generated intellectual property, with Yuezhi Technology holding exclusive production rights for the robots and Yaoshi Bang having exclusive sales rights in the pharmaceutical sector [1][2] Group 2 - The board of directors believes that the strategic partnership will facilitate resource integration and collaborative innovation, enhancing technological development in the industry and promoting social health [2] - Yaoshi Bang, founded in 2015, focuses on empowering various enterprises in the pharmaceutical supply chain with digital and intelligent solutions, while Yuezhi Technology, also established in 2015, has developed over twenty collaborative robots for various sectors [2] - According to a report by Zhaoshi Industry Consulting, the global collaborative robot market in the healthcare sector is expected to reach $373.2 million by 2028, indicating significant growth potential in the pharmaceutical application of robotics [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 訂立戰略合作與業務部署協議 最新業務部署進展 此公告乃藥師幫股份有限公司（「本公司」，與 其 附 屬 公 司 合 稱「本集團」）自願作 出，以 告 知 其 股 東 及 潛 在 投 資 者 有 關 本 集 團 若 干 業 務 發 展 之 最 新 情 況。 本公司董事會（「董事會」）欣 然 宣 佈，於2025年6月3日，本 集 團 與 深 圳 市 越 疆 科 技 股份有限公司（其H股於香港聯合交易所有限公司主板上市；股份代號：2432.HK） （「越疆科技」）訂立戰略合作與業務部署協議（「戰略協議」），開 啟 緊 密 戰 略 合 作， 並 已 展 開 具 體 項 目 的 部 署。 有關合作背景介紹 本集團創立於20 ...

Group 1 - As of June 3, a total of 105 stocks reached their 52-week highs, with Huayin International Holdings (00989), Dingyifeng Holdings (00612), and Youquhui Holdings (02177) leading the high rate at 57.26%, 37.93%, and 23.02% respectively [1] - The closing prices and highest prices for the top three stocks are as follows: Huayin International Holdings at 1.370 and 1.950, Dingyifeng Holdings at 0.770 and 0.800, and Youquhui Holdings at 3.550 and 3.580 [1] - Other notable stocks that reached their 52-week highs include China Antibody-B (03681) with a high rate of 21.62% and Fengcheng Holdings (02295) at 19.52% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Des Holdings (08437) showing the largest decline at -38.79%, followed by Dimi Life Holdings (01667) at -20.50% [3] - The closing prices and lowest prices for the top three stocks that reached their lows are: Des Holdings at 0.177 and 0.071, Dimi Life Holdings at 0.140 and 0.128, and Lujizhi Technology (01745) at 0.197 and 0.194 [3] - Other stocks with significant declines include GBA Group (00261) at -11.48% and Baide International (02668) at -10.88% [3]

Company Overview - Yaoshi Bang Co., Ltd. was established in 2015 and is the largest digital comprehensive service platform in China's outpatient pharmaceutical industry [2] - The company aims to empower participants in the outpatient pharmaceutical market through digitalization, including pharmaceutical companies, distributors, pharmacies, and grassroots medical institutions [2] - Yaoshi Bang's mission is to make quality medical products and services accessible at fair and transparent prices, enhancing the overall efficiency of the healthcare ecosystem [2] Financial Performance - As of December 31, 2024, Yaoshi Bang achieved total revenue of 17.904 billion yuan, a year-on-year increase of 5.49% [1] - The net profit attributable to shareholders was 30.013 million yuan, reflecting a significant year-on-year growth of 100.94% [1] - The gross profit margin stood at 10.13%, while the debt-to-asset ratio was 65.07% [1] Market Position and Valuation - Yaoshi Bang's stock price closed at 9.85 HKD per share, with a recent increase of 7.89% and a cumulative increase of 44.86% over the past month [1] - The company's price-to-earnings (P/E) ratio is 192.11, significantly higher than the industry average P/E ratio of 5.64 [1] - The company is rated "Buy" by Tianfeng Securities with a target price of 9.88 HKD [1] Industry Insights - The pharmaceutical and biotechnology industry has an average P/E ratio of 5.64, with a median of 5.97 [1] - Yaoshi Bang has established a vast digital pharmaceutical trading and service network, covering 491,000 pharmacies and 330,000 grassroots medical institutions, penetrating 98.9% of county areas and 91.2% of townships in China [2] - The monthly active buyers reached 433,000, indicating strong engagement in the digital pharmaceutical market [2]

Core Viewpoint - The company is experiencing a strong rebound in the Hong Kong pharmaceutical sector, leading to significant stock price increases and a projected turnaround to profitability in 2024 [3][4]. Group 1: Financial Performance - In 2024, the company reported an annual revenue of 17.904 billion yuan, a year-on-year increase of 5.5%, and an adjusted net profit of 157 million yuan, up 20%, achieving a net profit of 30.01 million yuan, marking a complete turnaround to profitability [3]. - The company’s brand promotion business generated a total transaction volume of approximately 717 million yuan from January to April 2024, representing a year-on-year growth of 108.1%, while the proprietary brand business reached 560 million yuan, up 532.3% [4]. Group 2: Strategic Initiatives - The company is focusing on its proprietary brand and brand promotion business, collaborating closely with upstream pharmaceutical companies to drive revenue growth [3]. - A share buyback plan was announced on May 7, with a total of 4.977 million shares repurchased for over 38.09 million Hong Kong dollars, reflecting positive expectations for its performance and market outlook [5]. Group 3: Market Outlook - According to projections, the Chinese out-of-hospital pharmaceutical distribution market is expected to exceed 1 trillion yuan by 2027, with digital pharmaceutical distribution reaching 358.3 billion yuan [5]. - The company has completed its warehousing and supply chain setup, moving past the phase of significant capital expenditure, and is expected to enhance its profitability through its brand promotion business [5].

Summary of Key Points Core Viewpoint - As of May 28, a total of 65 stocks reached their 52-week highs, with notable performances from Kingway Medical Holdings (08559), China Silver Technology (00515), and Honghui Group (00183) leading the list with high rates of increase [1]. Group 1: Stocks Reaching 52-Week Highs - Kingway Medical Holdings (08559) achieved a closing price of 0.027 with a peak of 0.045, marking a high rate of 32.35% [1]. - China Silver Technology (00515) closed at 0.280, reaching a maximum of 0.305, resulting in a high rate of 28.15% [1]. - Honghui Group (00183) had a closing price of 0.255, with a peak price of 0.255, reflecting a high rate of 27.50% [1]. - Other notable stocks include Emperor Watch and Jewellery (00887) with a high rate of 27.14% and Sogo Department Store (00312) at 21.79% [1]. Group 2: Additional Stocks with Significant Increases - Lehua Entertainment (02306) reached a high rate of 13.73% with a closing price of 2.540 [1]. - Kingway Medical (08143) had a closing price of 0.124 and a peak of 0.230, resulting in a high rate of 10.05% [1]. - Other stocks with notable increases include Zhu Feng Gold (01815) at 6.98% and Yaoshi Bang (09885) at 6.68% [1]. Group 3: Stocks with Lower Performance - The report also includes stocks that did not perform as well, with some reaching their 52-week lows, such as China Parenting Network (01736) with a low rate of -14.40% [2]. - XI Nan Tes-U (09366) and XI Nan Tes (07366) also showed declines of -10.08% and -8.60% respectively [2]. - Other stocks like He Fu Hui Huang (00733) and Pai Ge Biomedical-B (02565) experienced decreases of -7.04% and -6.95% [2].

Core Viewpoint - The company, Yaoshi Bang, has successfully transitioned to profitability in 2024, showcasing strong growth and operational efficiency despite industry challenges [3][8]. Group 1: Business Performance - In 2024, Yaoshi Bang reported annual revenue of 17.904 billion yuan, a year-on-year increase of 5.5%, and an adjusted net profit of 157 million yuan, up 20% [3]. - The company's stock price has increased by over 68% year-to-date, reflecting a strong rebound in the Hong Kong pharmaceutical sector [3]. - The company has achieved a significant turnaround, with net profit reaching 30.01 million yuan, marking its first full-year profitability [3][8]. Group 2: Operational Efficiency - Yaoshi Bang has improved its operational efficiency, with accounts receivable turnover days decreasing from 3.9 days in 2021 to 1.3 days in 2024, and inventory turnover at 33.4 days [4]. - The company reported operating cash flow inflows of 98.2 million yuan in 2022, 451 million yuan in 2023, and 656 million yuan in 2024, indicating strong cash management [4]. - By the end of 2024, the company had 3.375 billion yuan in cash and cash equivalents, a year-on-year increase of 13.5% [4]. Group 3: Strategic Partnerships and Growth - The company has successfully launched its own brand and strategic partnerships, with self-owned brand transactions reaching 560 million yuan, a year-on-year increase of 532.3% [6]. - Yaoshi Bang's collaboration with key suppliers has enhanced market coverage and sales efficiency, contributing to its growth strategy [6]. - The company has established a comprehensive business model covering the outpatient pharmaceutical industry, with revenue growing from 3.252 billion yuan in 2019 to 17.904 billion yuan in 2024, reflecting a CAGR of 40.66% [8]. Group 4: Market Outlook and Confidence - The company announced a share buyback plan worth 100 million yuan, reflecting management's confidence in future performance [7]. - The chairman emphasized the commitment to digital transformation in the pharmaceutical supply chain, with expectations for significant market growth in the outpatient pharmaceutical sector [7]. - Analysts predict that the outpatient pharmaceutical market in China could exceed 1 trillion yuan by 2027, with digital pharmaceutical distribution reaching 358.3 billion yuan [7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 股份回購 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日 及2025年5月26日的公告（「該等公告」）， 內容有關（其 中 包 括）其 股 份 回 購 計 劃。本 公 司 將 根 據 市 況 及 資 金 安 排，於 市 場 上回購總額最多1億 港 元 的 股 份。除 另 有 說 明 者 外，本 ...

| 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | | 於下列日期開始時的結存(註1) | 2025年5月26日 | | 681,949,995 | | | 0 | | | | 681,949,995 | | 1). 其他 (請註明) | | | | | % | | | | | | | ...